Peptide Monograph
MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
At a Glance
Mechanism of Action
MOTS-c is a 16-amino acid peptide encoded by the mitochondrial DNA within the 12S rRNA gene (MT-RNR1). It was discovered in 2015 as the first mitochondrial-derived peptide (MDP) shown to regulate nuclear gene expression, establishing a novel paradigm of retrograde signaling from mitochondria to the nucleus.[1] This discovery challenged the prevailing view that mitochondria function solely as downstream effectors of nuclear-encoded programs.
The primary molecular target of MOTS-c is the AMPK (5'-AMP-activated protein kinase) pathway. MOTS-c activates AMPK, the master cellular energy sensor, which in turn promotes glucose uptake, enhances fatty acid oxidation, and inhibits gluconeogenesis. Through AMPK activation, MOTS-c improves insulin sensitivity and whole-body glucose homeostasis, effects that have been demonstrated in both lean and diet-induced obese mouse models.[1][2]
MOTS-c targets the folate-methionine cycle, a critical one-carbon metabolic pathway. By inhibiting the folate cycle, MOTS-c leads to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is a well-established endogenous AMPK activator. This mechanism links mitochondrial signaling to cellular metabolic reprogramming and explains much of the peptide's metabolic activity.[1]
A key physiological observation is that MOTS-c functions as an exercise mimetic. Circulating MOTS-c levels increase during exercise in both skeletal muscle and plasma, and the peptide translocates to the nucleus in response to metabolic stress, where it regulates expression of nuclear genes involved in glucose metabolism and antioxidant defense. This exercise-responsive behavior positions MOTS-c as a potential mediator of exercise's metabolic benefits.[3]
MOTS-c levels have been shown to decline with age and in states of metabolic disease, including obesity and type 2 diabetes. This age-related decline has led to the hypothesis that MOTS-c depletion may contribute to the metabolic dysfunction associated with aging, and that exogenous MOTS-c administration could serve as a restorative intervention.[4]
Evidence Summary
MOTS-c research is at a very early stage. All efficacy data comes from animal models and in vitro studies. No published human randomized controlled trials exist as of this writing. All claims about therapeutic potential in humans are extrapolated from preclinical data. Readers should weigh this limitation heavily.
Animal and In Vitro Studies
The discovery paper by Lee et al. (2015) demonstrated that MOTS-c administration in mice prevented age-dependent and high-fat-diet-induced insulin resistance, improved glucose homeostasis as measured by glucose tolerance testing, and enhanced exercise capacity. Mice treated with MOTS-c showed increased energy expenditure and reduced body weight gain when fed a high-fat diet.[1]
Kim et al. further characterized MOTS-c's mechanism of AMPK activation, demonstrating that the peptide's effects on glucose metabolism were AMPK-dependent and involved inhibition of the folate-methionine cycle. In cell culture studies, MOTS-c treatment led to significant increases in glucose uptake in skeletal muscle cells.[2]
Reynolds et al. established the translational relevance of MOTS-c by demonstrating that circulating levels of the peptide decline with age in both human and mouse plasma. Furthermore, MOTS-c levels were found to be lower in individuals with metabolic disease compared to healthy controls, suggesting a potential biomarker role and therapeutic rationale for supplementation.[4]
Zempo et al. identified genetic polymorphisms in the mitochondrial region encoding MOTS-c (m.1382A>C) that were associated with longevity in a Japanese population, providing indirect evidence for MOTS-c's role in healthy aging.[5]
Human Evidence
No completed human clinical trials of exogenous MOTS-c administration have been published in peer-reviewed literature as of this writing. The human data is limited to observational studies measuring endogenous MOTS-c levels in different populations (healthy vs. metabolic disease, young vs. old). While these correlative findings are suggestive, they do not establish that exogenous MOTS-c supplementation would produce therapeutic benefits in humans. The pharmacokinetics, optimal dosing, and safety profile of MOTS-c in humans remain entirely unknown from a clinical evidence standpoint.
Primary Uses (in Research)
Based on the available preclinical literature, MOTS-c has been investigated for the following applications:
- Metabolic regulation and insulin sensitization — Improved glucose homeostasis, enhanced insulin sensitivity, and prevention of diet-induced obesity in mouse models through AMPK activation.[1]
- Exercise mimetic — Replication of exercise-induced metabolic benefits, including increased energy expenditure and improved mitochondrial function, in sedentary animals.[3]
- Age-related metabolic decline — Restoration of MOTS-c levels that decline with age, potentially counteracting age-associated insulin resistance and metabolic dysfunction.[4]
- Obesity prevention — Reduction of weight gain and improvement of metabolic parameters in high-fat-diet-fed mice.[1]
- Mitochondrial function — Enhancement of mitochondrial bioenergetics and cellular stress response through retrograde mitochondrial-nuclear signaling.[2]
Contraindications
No established human contraindications exist because insufficient clinical data is available. The following precautions are based on the peptide's known pharmacological mechanisms and represent theoretical concerns:
- Pregnancy and lactation — No reproductive toxicology or teratogenicity studies have been conducted. No safety data exists for use during pregnancy or breastfeeding. Use is strongly discouraged.
- Active malignancy — The role of AMPK in tumor metabolism is complex and context-dependent. AMPK activation can be both tumor-suppressive and tumor-promoting depending on the cancer type and stage. Until this is better understood, use in individuals with active cancer should be avoided.
- Hypoglycemia risk — MOTS-c enhances glucose uptake and insulin sensitivity. Individuals on insulin or sulfonylureas may be at increased risk of hypoglycemia. Blood glucose monitoring is advisable.
- Pediatric use — No safety or efficacy data exists for use in children or adolescents.
- Insufficient safety data — Given the complete absence of human clinical trials, all use carries unknown risk. The long-term consequences of exogenous MOTS-c administration are entirely uncharacterized.
Standard Protocols
The following protocols are derived from animal study dosing extrapolations and community-reported protocols. No dosing regimen has been validated in human clinical trials. These should not be interpreted as medical prescriptions.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Metabolic support (general) | SubQ (abdomen) | 5 mg | 3x/week | 4–8 weeks |
| Metabolic support (higher dose) | SubQ (abdomen) | 10 mg | 3–5x/week | 4–8 weeks |
| Exercise performance | SubQ (abdomen or thigh) | 10 mg | 5x/week (training days) | 4–6 weeks |
Common Stacks & Synergies
In the peptide research and self-experimentation community, MOTS-c is sometimes combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined use:
- MOTS-c + Humanin — Humanin is another mitochondrial-derived peptide with cytoprotective and metabolic effects. The rationale for combining them is that they target complementary aspects of mitochondrial signaling and metabolic regulation.
- MOTS-c + Metformin — Both MOTS-c and metformin activate AMPK, but through different mechanisms. Some researchers hypothesize synergistic metabolic effects, though the risk of compounded hypoglycemia should be considered.
- MOTS-c + NAD+ precursors (NMN/NR) — NAD+ precursors support mitochondrial function and energy metabolism. The theoretical synergy involves enhancing mitochondrial health from multiple angles.
- MOTS-c + Exercise — Given MOTS-c's role as an exercise mimetic, combining supplementation with regular physical activity is frequently discussed as potentially amplifying metabolic benefits.
Preparation & Administration
MOTS-c is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 5 mg or 10 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.
Reconstitution
For a standard 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 500 mcg. Given the higher dosing requirements of MOTS-c (milligram range), larger injection volumes may be needed. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Preferred injection sites include the abdomen and anterior thigh. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Side Effects & Adverse Events
MOTS-c has not been tested in formal human clinical trials. The adverse event profile described below is drawn from animal studies and uncontrolled self-reports. Without human pharmacovigilance data, the true incidence and severity of side effects cannot be established.
In published animal studies, MOTS-c has not demonstrated overt toxicity at the doses used for metabolic research. However, formal toxicology studies with dose-escalation and long-term exposure have not been published.[1]
Self-reported side effects from community use (unverified):
- Injection site reactions (redness, mild swelling, pain at injection site)
- Mild fatigue, particularly during the initial days of use
- Transient lightheadedness
- Mild gastrointestinal discomfort (rare)
The absence of systematic human safety data means rare or delayed adverse effects could go entirely undetected. The long-term consequences of exogenous AMPK activation via MOTS-c are unknown.
Drug Interactions
No formal drug interaction studies have been conducted with MOTS-c in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:
- Insulin and insulin secretagogues (sulfonylureas) — MOTS-c enhances insulin sensitivity and glucose uptake via AMPK activation. Co-administration with insulin or sulfonylureas may increase hypoglycemia risk. Blood glucose monitoring is strongly recommended.
- Metformin — Both metformin and MOTS-c activate AMPK, albeit through different mechanisms. Combined use could theoretically produce additive or synergistic effects on glucose metabolism, potentially increasing the risk of lactic acidosis or hypoglycemia.
- Folate and methotrexate — MOTS-c targets the folate-methionine cycle. Interactions with folate supplements or folate-antagonist drugs (e.g., methotrexate) are theoretically possible but unstudied.[1]
- Other AMPK activators (AICAR, berberine) — Additive AMPK activation could amplify metabolic effects beyond what is intended or safe.
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Optimal; stable for months to years if sealed |
| Lyophilized powder (sealed) | Frozen (–20°C / –4°F) | Extended long-term storage |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 28 days |
| Reconstituted solution | Room temperature | Not recommended; use within 24–48 hours if unavoidable |
Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Available only as a research chemical labeled "not for human consumption."
- Clinical trial status — MOTS-c is at a very early research stage. No IND (Investigational New Drug) applications have been publicly disclosed as of this writing.
- WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026, but could potentially fall under S0 ("non-approved substances") depending on interpretation.
- European Union — Not approved as a medicinal product. Available as a research chemical in some jurisdictions.
- General status — MOTS-c occupies the typical research chemical legal gray area. It is legal to purchase for research purposes in most jurisdictions but not legal to market for human therapeutic use.
Open Questions
MOTS-c research is in its early stages. Significant gaps remain in the evidence base:
- Complete absence of human clinical trials — No pharmacokinetic, safety, or efficacy data from controlled human studies exists. This is the most fundamental limitation.
- Optimal dosing and pharmacokinetics — The half-life, bioavailability, tissue distribution, and dose-response relationship of exogenous MOTS-c in humans are entirely unknown.
- Long-term safety of chronic AMPK activation — While acute AMPK activation is generally beneficial, the consequences of sustained exogenous AMPK activation via MOTS-c are unknown and could include unintended effects on cell growth and autophagy.
- Cancer implications — AMPK plays complex and context-dependent roles in tumor biology. Whether MOTS-c supplementation increases, decreases, or has no effect on cancer risk is a critical open question.
- Relationship to endogenous production — It is unclear whether exogenous MOTS-c supplementation downregulates endogenous mitochondrial production of the peptide, which could have implications for discontinuation effects.
- Interaction with exercise — Whether MOTS-c supplementation enhances, replaces, or interferes with the natural exercise-induced MOTS-c response is not established.
Bibliography
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-54. doi:10.1016/j.cmet.2015.02.009. PMID:25738459.
- Kim SJ, Mehta HH, Wan J, Kueber C, Sallam T, Yen K, Lee C, Cohen P. "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging (Albany NY). 2018;10(6):1239-1256. doi:10.18632/aging.101463. PMID:29886458.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benber B, Voisin S, Papadopoli DJ, Topisirovic I, Bhatt AP, Garsin DA, Merry TL, Lee C. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun. 2021;12(1):470. doi:10.1038/s41467-020-20790-0. PMID:33473109.
- Reynolds JC, Bwiza CP, Lee C. "Mitonuclear genomics and aging." Hum Genet. 2020;139(3):381-399. doi:10.1007/s00439-020-02119-5. PMID:32002679.
- Zempo H, Fuku N, Nishida Y, Murakami H, Miyachi M. "Mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" Genes Cells. 2016;21(1):49-53. doi:10.1111/gtc.12331. PMID:26663582.